BCTXZ
BriaCell Therapeutics Corp. WarrantNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
1.63
52W High
$1.14
52W Low
$0.06
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About BriaCell Therapeutics Corp. Warrant
BriaCell Therapeutics Corp. is a clinical-stage biotechnology firm specializing in the development of innovative immunotherapies aimed at treating cancer, particularly breast cancer. The company's lead product candidate, Bria-IMT, has exhibited promising efficacy in early-stage clinical trials, highlighting BriaCell's dedication to addressing critical unmet needs in oncology. With a robust research and development framework and a seasoned leadership team, BriaCell is strategically positioned to foster significant advancements in cancer therapeutics and improve patient outcomes in an evolving market landscape.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-30.63M |
| Operating Margin | 0.00% |
| Return on Equity | -179.20% |
| Return on Assets | -89.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.26 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $6.41M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
58.72%
HV 20-Day
93.32%
HV 30-Day
104.48%
HV 60-Day
173.22%
HV Rank
—
Volatility is currently contracting
Data last updated: 5/25/2026